Skip to content

Study · Animal study (in vivo) · mouse · 2017

10 results

MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA.

Zhai D, Ye Z, Jiang Y, Xu C, Ruan B, Yang Y, Lei X, Xiang A, Lu H, Zhu Z, Yan Z, Wei D, Li Q, Wang L, Lu Z

Molecular immunology1 Nov 2017Cited by 65 (Europe PMC)

PMID29096170 (opens in a new tab)DOI10.1016/j.molimm.2017.10.017 (opens in a new tab)PepBankPUB-29096170
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In MRSA-challenged mice, MOTS‑c significantly improved the survival rate.

    In plain wordsIn mice infected with MRSA, MOTS‑c improved survival.

    Peptide
    MOTS-c
    Outcome
    IncreaseSurvival rate
    Study

    mousen: not reported in source

    MRSA-challenged mice
    Outcome group
    Mortality · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we demonstrated that a Mitochondria-derived peptide (MOTS-c) could significantly improve the survival rate and decrease bacteria loads in MRSA-challenged mice, accompanied with declined levels of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, but with increased level of anti-inflamm…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In MRSA-challenged mice, MOTS‑c significantly decreased bacterial loads.

    In plain wordsIn mice infected with MRSA, MOTS‑c lowered the amount of bacteria.

    Peptide
    MOTS-c
    Outcome
    DecreaseBacterial load
    Study

    mousen: not reported in source

    MRSA-challenged mice
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we demonstrated that a Mitochondria-derived peptide (MOTS-c) could significantly improve the survival rate and decrease bacteria loads in MRSA-challenged mice, accompanied with declined levels of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, but with increased level of anti-inflamm…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In MRSA-challenged mice, MOTS‑c came with lower levels of TNF-α.

    In plain wordsIn mice infected with MRSA, MOTS‑c came with lower levels of the inflammation signal TNF-α.

    Peptide
    MOTS-c
    Outcome
    DecreaseTNF-α level
    Study

    mousen: not reported in source

    MRSA-challenged mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we demonstrated that a Mitochondria-derived peptide (MOTS-c) could significantly improve the survival rate and decrease bacteria loads in MRSA-challenged mice, accompanied with declined levels of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, but with increased level of anti-inflamm…
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In MRSA-challenged mice, MOTS‑c came with lower levels of IL-6.

    In plain wordsIn mice infected with MRSA, MOTS‑c came with lower levels of the inflammation signal IL-6.

    Peptide
    MOTS-c
    Outcome
    DecreaseIL-6 level
    Study

    mousen: not reported in source

    MRSA-challenged mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we demonstrated that a Mitochondria-derived peptide (MOTS-c) could significantly improve the survival rate and decrease bacteria loads in MRSA-challenged mice, accompanied with declined levels of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, but with increased level of anti-inflamm…
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In MRSA-challenged mice, MOTS‑c came with lower levels of IL-1β.

    In plain wordsIn mice infected with MRSA, MOTS‑c came with lower levels of the inflammation signal IL-1β.

    Peptide
    MOTS-c
    Outcome
    DecreaseIL-1β level
    Study

    mousen: not reported in source

    MRSA-challenged mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we demonstrated that a Mitochondria-derived peptide (MOTS-c) could significantly improve the survival rate and decrease bacteria loads in MRSA-challenged mice, accompanied with declined levels of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, but with increased level of anti-inflamm…
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In MRSA-challenged mice, MOTS‑c came with a higher level of the anti-inflammatory cytokine IL-10.

    In plain wordsIn mice infected with MRSA, MOTS‑c came with a higher level of the anti-inflammatory signal IL-10.

    Peptide
    MOTS-c
    Outcome
    IncreaseIL-10 level
    Study

    mousen: not reported in source

    MRSA-challenged mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we demonstrated that a Mitochondria-derived peptide (MOTS-c) could significantly improve the survival rate and decrease bacteria loads in MRSA-challenged mice, accompanied with declined levels of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, but with increased level of anti-inflamm…
  7. 07LabIn vitro (cells)Activity measurement

    MOTS‑c enhanced the bactericidal capacity of macrophages.

    In plain wordsIn cells, MOTS‑c improved the ability of macrophages to kill bacteria.

    Peptide
    MOTS-c
    Outcome
    IncreaseBactericidal capacity of macrophages
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover this peptide enhanced bactericidal capacity of macrophages.
  8. 08LabIn vitro (cells)Mechanism

    In macrophages, MOTS‑c inhibited the phosphorylation of mitogen-activated protein kinases.

    In plain wordsIn cells, MOTS‑c reduced the activation of MAPK signaling in macrophages.

    Peptide
    MOTS-c
    Outcome
    DecreaseMAPK phosphorylation
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c inhibited the phosphorylation mitogen-activated protein kinases (MAPK)
  9. 09LabIn vitro (cells)Mechanism

    In macrophages, MOTS‑c enhanced the expression of aryl hydrocarbon receptor.

    In plain wordsIn cells, MOTS‑c raised the amount of the aryl hydrocarbon receptor in macrophages.

    Peptide
    MOTS-c
    Outcome
    IncreaseAhR expression
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    enhanced the expression of aryl hydrocarbon receptor (AhR) and signal transducer and activator of transcriptional 3 (STAT3) in macrophages.
  10. 10LabIn vitro (cells)Mechanism

    In macrophages, MOTS‑c enhanced the expression of STAT3.

    In plain wordsIn cells, MOTS‑c raised the amount of STAT3 in macrophages.

    Peptide
    MOTS-c
    Outcome
    IncreaseSTAT3 expression
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    enhanced the expression of aryl hydrocarbon receptor (AhR) and signal transducer and activator of transcriptional 3 (STAT3) in macrophages.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.